医学
射血分数
心肌梗塞
内科学
心脏病学
临床终点
危险系数
置信区间
随机对照试验
再灌注治疗
子群分析
荟萃分析
代理终结点
心力衰竭
前瞻性队列研究
心肌梗死并发症
临床试验
梗塞
心肌梗死诊断
梅德林
药物治疗
作者
L D Neira Chunga,G Vasquez Tirado,D Moncada Gutierrez,M Morales Piscoya
标识
DOI:10.1093/eurheartj/ehag785.4105
摘要
Abstract Background Beta-blockers are a cornerstone of secondary prevention following an acute myocardial infarction (AMI), with well-established benefits in patients with reduced left ventricular ejection fraction (LVEF). However, in the contemporary era of early reperfusion and guideline-directed medical therapy, the effectiveness of long-term beta-blocker therapy in patients with preserved or mildly reduced LVEF remains uncertain, as existing evidence is limited and inconsistent. Purpose To systematically evaluate the association between beta-blocker therapy and major cardiovascular outcomes in patients with acute myocardial infarction and preserved or mildly reduced left ventricular ejection fraction. Methods We conducted a systematic review and meta-analysis of randomised controlled trials in accordance with PRISMA guidelines and prospectively registered in PROSPERO. We searched for studies published up to 30 October 2025 across five electronic databases (PubMed, Embase, Scopus, Web of Science, and ScienceDirect), using a PECO/PICO-based search strategy. Four studies met the inclusion criteria and were included in the quantitative synthesis and meta-analysis. Random-effects meta-analyses were performed using hazard ratios (HRs) with 95% confidence intervals (CIs). The certainty of evidence was assessed using the GRADE approach. Results This meta-analysis included four studies comprising a total of 18,504 patients with a history of AMI and an LVEF ≥40%. Among these, 2,223 patients had mildly reduced LVEF, while 15,908 had preserved LVEF. Beta-blocker therapy was not associated with a significant reduction in the primary composite endpoint (all-cause mortality, reinfarction, and cardiovascular hospitalisation) in patients with LVEF ≥40% (HR 0.90; 95% CI 0.81–1.01). Subgroup analyses demonstrated no significant reduction in the primary composite endpoint among patients with preserved LVEF (HR 0.94; 95% CI 0.87–1.03). However, in patients with mildly reduced LVEF, beta-blocker therapy was associated with a significant reduction in the primary composite endpoint (HR 0.82; 95% CI 0.70–0.97). Conclusions In this meta-analysis of randomised controlled trials, beta-blocker therapy was not associated with a significant reduction in the primary composite endpoint, nor in individual outcomes such as mortality or reinfarction, among patients with preserved or mildly reduced LVEF following AMI. The apparent benefit observed in patients with mildly reduced LVEF derives from subgroup analysis and should be interpreted with caution within the context of an overall neutral effect.PRISMA flow diagram and Risk of BiasForest plots and sensitivity analyses
科研通智能强力驱动
Strongly Powered by AbleSci AI